AFG
GENB

Albion Financial Group’s Generate Biomedicines GENB Stock Holding History

Albion Financial Group’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$81.9K Hold
4,854
– – ﹤0.01% 245
2026
Q1 		$60.7K Buy
+4,854
New +$59.3K ﹤0.01% 251

Other funds holding GENB

AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
MFG
Magnus Financial Group New York $1.41B AUM 23.4% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return

Albion Financial Group's GENB Position: Q2 2026 in Review

Albion Financial Group held its Generate Biomedicines (GENB) position steady in Q2 2026 at 4,854 shares worth $81.9K. The position accounts for ﹤0.01% of the portfolio, ranked #245.

Albion Financial Group first reported a position in GENB in Q1 2026 and has held it in 2 quarters since. 12 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

  • Albion Financial Group held 4,854 shares of Generate Biomedicines worth $81.9K as of Q2 2026.
  • Albion Financial Group left its Generate Biomedicines share count unchanged in Q2 2026.
  • Generate Biomedicines made up ﹤0.01% of Albion Financial Group's portfolio in Q2 2026, its #245 holding.
  • Albion Financial Group first reported a position in Generate Biomedicines in Q1 2026 and has held it in 2 quarters since.
  • 12 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on Albion Financial Group's 13F filing for Q2 2026, filed 22 Jul 2026.